29,914 Shares in Bristol-Myers Squibb (NYSE:BMY) Purchased by Mirabella Financial Services LLP

Mirabella Financial Services LLP purchased a new stake in Bristol-Myers Squibb (NYSE:BMY) in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 29,914 shares of the biopharmaceutical company’s stock, valued at approximately $1,692,000.

A number of other hedge funds also recently modified their holdings of BMY. Fairway Wealth LLC bought a new position in shares of Bristol-Myers Squibb during the 4th quarter worth approximately $28,000. Comprehensive Financial Planning Inc. PA acquired a new position in Bristol-Myers Squibb during the fourth quarter worth $34,000. Westend Capital Management LLC bought a new position in shares of Bristol-Myers Squibb during the fourth quarter valued at $38,000. Tacita Capital Inc bought a new stake in shares of Bristol-Myers Squibb in the 4th quarter worth about $39,000. Finally, M Holdings Securities Inc. acquired a new stake in shares of Bristol-Myers Squibb during the 4th quarter worth about $39,000. Institutional investors own 76.41% of the company’s stock.

Insiders Place Their Bets

In related news, EVP Samit Hirawat purchased 1,823 shares of the stock in a transaction dated Friday, February 14th. The stock was bought at an average cost of $54.84 per share, with a total value of $99,973.32. Following the purchase, the executive vice president now directly owns 63,932 shares in the company, valued at $3,506,030.88. The trade was a 2.94 % increase in their position. The purchase was disclosed in a document filed with the SEC, which is available at this link. Company insiders own 0.07% of the company’s stock.

Bristol-Myers Squibb Stock Down 0.3 %

Shares of NYSE:BMY opened at $49.24 on Monday. The company has a debt-to-equity ratio of 2.90, a current ratio of 1.25 and a quick ratio of 1.15. The stock has a market cap of $100.18 billion, a price-to-earnings ratio of -11.14, a P/E/G ratio of 2.07 and a beta of 0.41. The company has a 50 day moving average of $56.98 and a 200-day moving average of $56.68. Bristol-Myers Squibb has a one year low of $39.35 and a one year high of $63.33.

Bristol-Myers Squibb (NYSE:BMY) last released its earnings results on Thursday, February 6th. The biopharmaceutical company reported $1.67 EPS for the quarter, topping analysts’ consensus estimates of $1.47 by $0.20. Bristol-Myers Squibb had a negative net margin of 18.53% and a positive return on equity of 13.93%. On average, sell-side analysts forecast that Bristol-Myers Squibb will post 6.74 earnings per share for the current year.

Bristol-Myers Squibb Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Thursday, May 1st. Shareholders of record on Friday, April 4th will be paid a $0.62 dividend. This represents a $2.48 annualized dividend and a yield of 5.04%. The ex-dividend date is Friday, April 4th. Bristol-Myers Squibb’s payout ratio is -56.11%.

Wall Street Analyst Weigh In

BMY has been the topic of a number of recent analyst reports. Truist Financial boosted their price target on shares of Bristol-Myers Squibb from $62.00 to $65.00 and gave the company a “buy” rating in a research report on Wednesday, January 8th. Citigroup boosted their target price on Bristol-Myers Squibb from $60.00 to $65.00 and gave the stock a “neutral” rating in a report on Tuesday, January 28th. UBS Group dropped their price target on Bristol-Myers Squibb from $60.00 to $54.00 and set a “neutral” rating for the company in a report on Friday, April 11th. Wells Fargo & Company boosted their price objective on Bristol-Myers Squibb from $60.00 to $62.00 and gave the stock an “equal weight” rating in a research note on Friday, February 7th. Finally, The Goldman Sachs Group restated a “neutral” rating and set a $55.00 target price (down previously from $67.00) on shares of Bristol-Myers Squibb in a report on Tuesday, April 8th. Two analysts have rated the stock with a sell rating, eleven have issued a hold rating, four have assigned a buy rating and three have issued a strong buy rating to the company’s stock. According to data from MarketBeat, Bristol-Myers Squibb has an average rating of “Hold” and an average target price of $57.67.

About Bristol-Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.